FDA-approved for three indications with multiple active-comparator trials, cardiovascular outcomes data, and extensive post-marketing surveillance
In addition, the NMF levels were increased at 12 weeks compared with placebo-control levels
Four proline residues, including an unusual triple-proline sequence, give BPC-157 exceptional stability
Experience advanced, compassionate care for your intimate wellnessonly at Fountain of You MD, serving Virginia Beach, Chesapeake, and the Hampton Roads community.
2 All three doses met the primary endpoint, with participants loosing an average of 29.8 lbs (12.7%) on the 4 mg dose, 45.4 lbs (19.1%) on the 9 mg dose, and 49.6 lbs (20.8%) on the 12 mg dose, compared to 9.3 lbs (4.0%) on placebo